1 recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Recruiting 1 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myeloproliferative Disorders (1)
Bone Marrow Diseases (1) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Dasatinib (1) · Imatinib Mesylate (1) · asciminib (1) · bosutinib (1) · nilotinib (1)
Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Lebanon (1) · Malaysia (1) · Mexico (1)
2023 (1)